Shionogi's COVID-19 vaccine matches Pfizer's Comirnaty in booster trial BeiGene's hematology CMO resigns in wake of solid tumor switch Synairgen's NIH-sponsored COVID-19 trial paused a day after SAB study nixed completely Sponsored: The Importance of the Patient in Advancing Care in Rare Diseases Pardes poaches former Dermira CEO Thomas Wiggans amid rocky ride at stock market vTv CEO resigns 4 months into job after slashing workforce, refocusing pipeline Foresite Labs' new $173M fund to bankroll fewer startups but 'big ideas' fueled by data Bristol Myers Squibb to consolidate R&D units in San Diego in new complex Billionaire Sackler family enters $6B opioid deal with support from holdout states 3 in 4 infusion pumps vulnerable to cyberattacks: study Senate narrowly votes to get rid of COVID-19 national emergency A2 Bio's activator-blocker CAR-T cell therapies show early promise in solid cancers Chutes & Ladders—Merck chief patient officer to retire to become CEO of NIH nonprofit Fierce Pharma Asia—J&J, Legend's CAR-T nod; Biocon's $3.3B Viatris biosimilar buy; Sanofi-Adagene tie-up Featured Story | By Nick Paul Taylor Shionogi’s COVID-19 vaccine candidate has held its own against Pfizer’s Comirnaty in a study of the effect of booster shots on antibody levels, offering the company encouragement as it barrels toward a filing for approval of S-268019 in Japan. read more |
| |
|---|
|
Top Stories By Nick Paul Taylor BeiGene’s hematology chief medical officer is hitting the exit. Almost six years after joining BeiGene, Jane Huang has handed in her resignation shortly after the replacement of her solid tumor counterpart. read more By Max Bayer A day after axing a study of SAB Biotherapeutics' COVID-19 antibody, the National Institutes of Health has placed another arm of the trial on hold, this time for Synairgen’s inhaled medicine. read more Sponsored by: Ipsen Read more to learn about Ipsen's commitment to the rare disease community and to ensuring their patients have a voice. read more By Kyle LaHucik Pardes Biosciences has a new face at the helm as the COVID-19 antiviral maker tries to rebound from a rough few weeks in which its stock has nearly halved. read more By Kyle LaHucik Deepa Prasad has resigned as CEO and president of vTv Therapeutics just four months into the job after having prioritized the biotech's pipeline to focus on Type 1 diabetes and having laid off 65% of the company in December. read more By Kyle LaHucik Foresite Labs secured $173 million to fund its own precision medicine companies, platform biotechs and healthcare services startups. The incubator has so far revealed Alumis (formerly Esker Therapeutics), Interline Therapeutics, TenSixteenBio and Sestina Bio. read more By Kevin Dunleavy Bristol Myers Squibb will soon take up residence in a new R&D campus in San Diego, California, leasing a 427,000 square foot complex in the University Town Center near La Jolla. The agreement will allow BMS to consolidate its R&D units in the area under one roof. read more By Eric Sagonowsky When OxyContin maker Purdue Pharma and its founding family inked a $4.5 billion opioid settlement back in September, the judge overseeing the case called it a "bitter result." Now, thanks to an appeal and extended talks, the settlement just got a lot bigger. read more By Conor Hale Palo Alto Networks used scans of more than 200,000 smart infusion pumps and discovered that 75% had at least one known and publicly documented security gaps. read more By Robert King The Senate narrowly passed a resolution calling for an end to the COVID-19 national emergency, which garnered a White House veto threat. read more By Angus Liu By leveraging a unique genetic feature that separates tumors from normal cells, scientists at A2 Biotherapeutics designed dual-signal CAR-T cells to tackle solid cancers. They have reported promising early results for two candidates. read more By Kyle LaHucik Merck's chief patient officer, Julie Gerberding, a former CDC director, will leave to become CEO of the Foundation for the National Institutes of Health. Pardes Biosciences named ex-Dermira CEO Thomas Wiggans its new CEO. And Akari Therapeutics CEO Clive Richardson is leaving and will be replaced by Rachelle Jacques. read more By Angus Liu Legend Biotech and Janssen's CAR-T therapy Carvykti has won an FDA go-ahead to challenge Bristol Myers Squibb in multiple myeloma. Biocon Biologics is buying partner Viatris' biosimilars business. Sanofi taps Adagene's "safe" antibody technology in a deal potentially worth $2.5 billion. And more. read more Resources Sponsored by: H1 Read why many MSLs are still challenged in developing integrated strategies to increase the volume of meaningful engagements. Download this industry report to find out what the top challenges are and suggestion strategies to solve them. Download now. Sponsored by: Oracle Health Sciences Learn about ways to break down regulatory roadblocks and get closer to 100% clarity on regulatory positions to advance decentralized clinical trials in research. Sponsored by: Oracle Health Sciences How to overcome top challenges faced in decentralized trials. Sponsored by: United Cargo The United Cargo team has made a commitment to pharmaceutical and medical partners that we are equipped to support their vaccine transportation needs safely and effectively across our expansive global and domestic network. The safety and security of these commodities is our priority, and we are proud to be a trusted partner in these efforts. Download infographic now. Sponsored by: Catalent How can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market? Sponsored by: Catalent Learn more about how the versatility of Softgel Technology helped a customer with a volatile compound. Sponsored by: Catalent What is the most suitable dosage form technology for the Oral Delivery of Lipid-Based Formulations? Sponsored by: Blue Matter What’s in store for the CNS therapeutics market in 2022? This paper looks ahead in Alzheimer’s, Parkinson’s, DMD, psychiatric disorders, pain, and more. Sponsored by: Catalent Biologics Ypsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar. Sponsored by: Catalent Biologics Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Fierce BD&L Summit for Life Sciences March 15-16, 2022 | San Francisco, CA Fierce Promotional Review Committee Compliance and Best Practices Summit April 12-14, 2022 | New Brunswick, NJ Fierce Trial Master File Summit May 2-4, 2022 | New Orleans, LA & Streaming Live Fierce Digital Pharma Engage June 14-15, 2022 | Huntington Beach, CA Fierce Pharma PR & Communications Summit West June 14, 2022 | Huntington Beach, CA Fierce Digital Pharma Innovation Week June 21-23, 2022 | Virtual Event Fierce Pharma PR & Communications Summit July 2022 | Location TBD (NYC Metro Area) Fierce MedTech Summit August 8-9, 2022 | Minneapolis, MN Promotional Review Committee Compliance and Best Practices Summit West (PRC West) September 2022 | San Diego, CA Medical Affairs Strategic Summit (MASS West) September 2022 | San Diego, CA Fierce Digital Pharma East October 18-20, 2022 | Philadelphia, PA & October 25-28, 2022 | Virtual Event Fierce Biotech Cell & Gene Therapy Forum October 19, 2022 | Virtual Event Fierce Pharma Marketing Awards October 19, 2022 | Philadelphia, PA Fierce Pharma Meeting Professionals Summit November 2-3, 2022 | Atlantic City, NJ Fierce European Trial Master File Summit November 14-16, 2022 | London, UK Fierce Launch Readiness for Medical Affairs & Communications Teams Summit November 30-December 1, 2022 | Virtual Event Fierce New Product Planning Summit November 30 - December 1, 2022 | Virtual Event Fierce JPM Week 2023 January 1, 2023 | 